Feature | Heart Valve Technology | May 25, 2017

Lotus TAVR System Shows Superior Efficacy to CoreValve in Global REPRISE III Trial

One-year data show Lotus is superior to CoreValve in stroke, death and paravalvular leak
 

The Boston Scientific Lotus TAVR Valve

May 25, 2017 — Positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris, demonstrated that the Boston Scientific Lotus Valve System, a transcatheter aortic valve implantation (TAVI) system, showed superiority over the Medtronic CoreValve TAVR System platform for the primary effectiveness endpoint and non-inferiority for the primary safety endpoint.

The REPRISE III clinical trial data will be used to support U.S. Food and Drug Administration (FDA) premarket approval for the Lotus Valve.

The primary effectiveness endpoint, a composite of all death, disabling stroke and moderate or greater paravalvular aortic leakage (PVL) at one year, was lower with the Lotus compared to the CoreValve platform (16.7 vs. 29%, p<0.001). The Lotus also demonstrated non-inferiority to CoreValve platform for the primary safety endpoint which was a composite of all-cause mortality, stroke, life-threatening and major bleeding events, stage two or three acute kidney injury or major vascular complications through 30 days.

The pre-specified secondary endpoint demonstrated the Lotus Valve system had significantly lower rates of moderate to severe PVL occurrences when compared to the CoreValve platform (2 vs. 11.1%, p<0.001).

“The excellent results seen in this large randomized trial, particularly the superior performance in efficacy and the continued demonstration of low PVL rates, further establish the advantages of the Lotus Valve system,” said Ted E. Feldman, M.D., director, cardiac catheterization laboratory, NorthShore University HealthSystem in Evanston, Illinois, and co-investigator of the REPRISE III trial. “With the Lotus Valve system, I have confidence that I can position the valve accurately in every case and achieve good outcomes for my patients.”

REPRISE III is the first head-to-head pivotal study comparing two different TAVI platforms: the Lotus Valve system and the CoreValve platform, including both CoreValve and EvolutR. It is a multi-center, randomized controlled trial that included 912 patients from the United States, Europe, Canada and Australia with severe aortic stenosis who were considered to be at high or extreme risk for surgical valve replacement.

“We are very excited by the performance of the Lotus Valve system in this trial as it represents a crucial piece of clinical evidence for the Lotus platform,” said Ian Meredith, M.D., executive vice president and global chief medical officer, Boston Scientific. “We believe that these data, along with upcoming findings to be shared from the RESPOND and RESPOND Extension studies, can further illustrate the unique clinical benefits that this system offers physicians for the treatment of patients.”

 

Related Content on the Lotus TAVR Valve System

REPRISE II Data Show Sustained Performance At One Year For Boston Scientific Lotus Valve System

Boston Scientific Lotus Valve System Demonstrates Extremely Low PVL Rates

Advances and Future Directions for Transcatheter Valves

Boston Scientific Gains European Approval for Next Generation Lotus Edge TAVR System

Boston Scientific Enrolls First Patients in U.S. Trial of Lotus Valve System

 

The Lotus Valve System is not available for sale in the United States.

For more information: www.bostonscientific.com

Related Content

Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Overlay Init